The Risk of Anal Carcinoma After Anogenital Warts in Adults Living With HIV
- PMID: 33439220
- PMCID: PMC7807394
- DOI: 10.1001/jamadermatol.2020.5252
The Risk of Anal Carcinoma After Anogenital Warts in Adults Living With HIV
Abstract
Importance: In the US, incidence of and mortality due to anal carcinoma are rising faster than for most other cancers. Identifying populations who have a higher risk of developing anal cancers is critical to target preventive interventions.
Objective: To assess the risk of developing anal carcinoma in adults living with HIV who have a history of anogenital warts.
Design, setting, and participants: This longitudinal cohort study included adults living with HIV from 14 clinics in Washington, DC, and at least 18 months of follow-up. Data were collected from January 1, 2011, to March 31, 2017, and analyzed from June 1, 2019, to October 31, 2020.
Exposures: Development of warts in the anal or genital region identified by diagnosis codes.
Main outcomes and measures: Individuals with anal carcinoma were identified by diagnosis codes or anal biopsy results.
Results: A total of 6515 participants were enrolled (4720 male [72.4%] at birth; mean [SD] age, 49.9 [12.7] years), and 383 (5.9%) developed anogenital warts during the study period. Patients who were diagnosed with anogenital warts were more likely to subsequently develop anal carcinoma (17 of 383 [4.4%]) compared with participants without a history of anogenital warts (17 of 6132 [0.3%]) (P < .001). After adjusting for covariates, the odds of developing anal carcinoma were 12.79 (95% CI, 6.19-26.45; P < .001) times higher in individuals with a history of anogenital warts compared with individuals without a history of anogenital warts.
Conclusions and relevance: These findings suggest that adults living with HIV who have a history of anogenital warts have a substantially increased risk of developing anal carcinoma. Clinicians should counsel individuals living with HIV who have anogenital warts on this risk.
Conflict of interest statement
Figures
Comment in
-
What Are We Waiting for?-Start Screening High-risk Individuals for Anal Cancer Now-Reply.JAMA Dermatol. 2021 Nov 1;157(11):1384. doi: 10.1001/jamadermatol.2021.3415. JAMA Dermatol. 2021. PMID: 34586348 No abstract available.
-
What Are We Waiting for?-Start Screening High-risk Individuals for Anal Cancer Now.JAMA Dermatol. 2021 Nov 1;157(11):1383-1384. doi: 10.1001/jamadermatol.2021.3832. JAMA Dermatol. 2021. PMID: 34586351 No abstract available.
References
-
- Lewis RM, Markowitz LE, Panicker G, Unger ER. Seroprevalence of human papillomavirus 6/11/16/18 among self-identified gay/bisexual men who have sex with men, men who have sex with women, and females, United States, 2003-2010. Clin Infect Dis. 2019;69(6):1011-1018. doi:10.1093/cid/ciy1002 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
